SureSeq myPanel™ NGS Custom AML Panel

SureSeq myPanel offers:

• Hybridisation-based panel delivering unparalleled coverage uniformity — detect low-frequency AML variants consistently with confidence and minimise the requirement for supplementary fill-in with Sanger sequencing
• Pre-optimised panels that meet your technical requirements and work with your samples — no more laborious in-house optimisation, decreasing assay development time
• Bespoke panel content — sequence only what’s relevant for your cancer research, increase throughput and save on sequencing reagents
• Panel content designed with experts and from current literature to target all relevant regions including intronic and splice sites — get the most comprehensive insight into disease-driving mutations

Getting started with SureSeq myPanel NGS Custom AML Panel could not be simpler...

Simply mix and match the genes or individual exons you require and get the most out of your sequencing runs.

Ordering Information

SureSeq: For research use only; not for use in diagnostic procedures.

Acute myeloid leukaemia (AML) is the most common type of leukaemia in adults. Our understanding of AML has been transformed in recent years to a disease classified largely based on genetic, genomic and molecular characteristics. Key genes identified include CEBPA, NPM1 and FLT3, with mutations in several additional genes being of interest from recent research.

Excellent Uniformity of Coverage of the CEBPA Gene

Mutations in the CEBPA gene are among the most common molecular alterations in AML. Sequencing of the CEBPA gene is often hampered by a repetitive nucleotide sequence and a high GC-rich content, which can lead to technical challenges in assay design, requiring a supplementary fill-in with Sanger sequencing. OGT’s expert bait design overcomes these issues, to offer a high level of uniform coverage for a notoriously difficult gene to sequence (Figure 1).

Figure 1: Illustration of the excellent uniformity of coverage of the CEBPA gene averaging ~3000x coverage. Depth of coverage per base (grey).  Targeted region (green). Gene coding region as defined by RefSeq (blue). GC percentage (red). Repeat regions, and those rich in GC (pink).

Sophisticated Bait Design Strategies

Genes such as FLT3 contain internal tandem duplications (ITDs) that are challenging to target because they are by nature repetitive and can be very long and are generally masked in most panel designs. To provide optimal results, OGT employs sophisticated bait design strategies to create additional probes both up- and down-stream of the repetitive region. The length of these probes is customised to provide the same isothermal properties as other probes in the panel, leading to improved performance. This facilitates the capture of sequences around the repeat masked areas, and because of the read lengths, can read through short repetitive regions (Figure 2).

Figure 2: In this example, the FLT3 ITD’s are clearly visible, (A) 72 bp ITD, (B) wild type, (C) 30 bp ITD and (D) 126 bp ITD.

Getting started with your next SureSeq myPanel Custom Cancer Panel could not be simpler...

Select from any of the following myPanel AML gene or exonic content

A panel you may be interested in:

Talk to us about your custom AML NGS panel requirements and let our expertise work in helping advance your cancer research.

If you are looking for an extended myeloid panel choose our SureSeq Myeloid Panel covering 25 genes of interest.

Ordering Information

For more information about the SureSeq AML NGS Panel or any cancer analysis products contact us at products@ogt.com.

We would like to thank UK NEQAS for providing OGT with validated research samples.

SureSeq: For research use only; not for use in diagnostic procedures.